Key result
LAAC is noninferior to NOACs for efficacy and reduces non-procedure-related bleeding in AF.
Why the study?
Does LAAC improve composite efficacy outcomes and reduce bleeding compared to NOAC therapy in patients with AF?
Does LAAC improve composite efficacy outcomes and reduce bleeding compared to NOAC therapy in patients with AF?
In patients with AF, LAAC is noninferior to NOAC therapy for composite efficacy and reduces non-procedure-related bleeding at 3 years.
Answers are grounded in this paper and cite their sources.
LAAC may reduce bleeding versus NOACs in AF without loss of efficacy; leaves open need for larger confirmatory trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raco et al. (2026) studied this question. LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 years in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: